The dawn phenomenon in diabetes: pathophysiology from periphery to central nervous system and circadian rhythm-based therapeutic strategies
Acta Diabetologica · 30.07.2026
DOI: 10.1007/s00592-026-02763-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Diabetologica, online erschienen am 30.07.2026. Verfasst von Yujue Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Provin…. Die Arbeit nennt 66 Literaturangaben. Gefördert von: the National Natural Science Foundation of China Youth Science Fund Project, the Young Talent Support Program of the China Association for Acupuncture-Moxibustion, the 2024 Jiangsu Provincial Young Scientific and Technological Talent Support Program.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The Dawn Phenomenon (DP) denotes the occurrence of spontaneous early-morning hyperglycemia in the absence of overnight hypoglycemia, or that necessitating an elevation in insulin to sustain normal morning blood glucose levels. Studies exhibit considerable variability, with some indicating that DP is a spontaneous occurrence reported in a substantial percentage of individuals. Patients with DP demonstrate increased average blood glucose variability over a 24-h period compared to those without DP, presenting considerable problems for clinical diabetes pharmacotherapy and nutritional regulation. Moreover, given the ambiguity surrounding the precise pathophysiology and targeted therapies for DP, therapeutic care predominantly emphasizes symptom alleviation. Conventional perspectives ascribe DP to physiological surges in the secretion of counterregulatory hormones, including cortisol, catecholamines, and growth hormone, in the early morning hours. These hormones enhance hepatic glucose production while concurrently diminishing peripheral tissue sensitivity to insulin. This article examines the contemporary pathophysiological underpinnings of DP to offer insights for clinical diagnosis and treatment in diabetes. This article focuses mainly on the dawn phenomenon in type 2 diabetes (T2DM), while evidence related to type 1 diabetes (T1DM) is addressed independently.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China.
- Department of Speciality Medicine, Ohio University, Athens, OH, 45701, USA. guanhuyang@gmail.com.
- Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China. xtc@njucm.edu.cn.
Förderung
- the National Natural Science Foundation of China Youth Science Fund Project
- the Young Talent Support Program of the China Association for Acupuncture-Moxibustion
- the 2024 Jiangsu Provincial Young Scientific and Technological Talent Support Program
- Talent Cultivation Program for Young Researchers, Key Laboratory of the Ministry of Education Project
Zitieren
APA
Wang, Y., Wang, S., Wang, W., Zhang, T., Xu, B., Yang, G., & Xu, T. (2026). The dawn phenomenon in diabetes: pathophysiology from periphery to central nervous system and circadian rhythm-based therapeutic strategies. Acta Diabetologica. https://doi.org/10.1007/s00592-026-02763-9
Vancouver
Wang Y, Wang S, Wang W, Zhang T, Xu B, Yang G, et al. The dawn phenomenon in diabetes: pathophysiology from periphery to central nervous system and circadian rhythm-based therapeutic strategies. Acta Diabetologica. 2026. doi:10.1007/s00592-026-02763-9
BibTeX
@article{Wang2026,
author = {Wang, Yujue and Wang, Shuaiyan and Wang, Weiqian and Zhang, Tongtong and Xu, Bin and Yang, Guanhu and Xu, Tiancheng},
title = {The dawn phenomenon in diabetes: pathophysiology from periphery to central nervous system and circadian rhythm-based therapeutic strategies},
journal = {Acta Diabetologica},
year = {2026},
doi = {10.1007/s00592-026-02763-9}
}
EUVIMED